Sponsorship bias in published pharmacoeconomic evaluations of national reimbursement negotiation drugs in China: a systematic review.

"Competing interests: All authors declare no competing interesets."

"Funding: The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors."

"We identified 174 generic names of drugs that were successfully added to China’s 2017–2020 NRDL after price negotiation () and defined these 174 drugs as the study’s target drug. Searches were performed in PubMed (MEDLINE), Embase and the Cochrane Library for studies published between January 2012 and January 2022. Systematic multistring search strategies were developed using a combination of text words and index terms in line with eligibility criteria to retrieve published studies. We employed three search term categories: 174 generic names of target drugs, China and Chinese region determiner and economic evaluation determiner, with searching fields restricted to title, abstract, keywords and Medical Subject Headings term (example shown in ). The review protocol was registered online with PROSPERO (CRD42022347795)."